BOND-003: Intravesical Cretostimogene Shows Durable Responses in High-Risk BCG-Unresponsive NMIBC

Presented by Dr. Trinity Bivalacqua at EAU25, the BOND-003 Phase 3 trial showcases updated data on intravesical cretostimogene grenadenorepvec, an innovative oncolytic immunotherapy for patients with high-risk BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
With a 75.5% complete response rate, a median duration of response of nearly 28 months, and 97.3% of patients remaining free from MIBC progression at 12 months, these findings mark a significant step forward in bladder-sparing therapy. The treatment was well-tolerated, with no Grade 3+ adverse events, and consistent efficacy across subgroups globally. Translational data confirmed sustained intravesical viral activity and immune engagement, without systemic shedding.

Thank you Dr. Bivalacqua for delivering this impactful presentation at EAU25.
For more information: https://lnkd.in/duCtn5AN